Carlsmed, Inc. (NASDAQ:CARL) Stock Has Average Price Target of $19.50 According to Brokerages

Carlsmed, Inc. (NASDAQ:CARL) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $19.50.

Several analysts have recently issued reports on CARL shares. Truist Financial lifted their target price on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. BTIG Research boosted their price objective on Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a report on Wednesday, November 4th.

Carlsmed Stock Performance

NASDAQ CARL opened at $14.71 on Wednesday. The stock has a 50-day moving average of $14.87 and a 200 day moving average of $12.52. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. Carlsmed has a twelve month low of $8.50 and a twelve month high of $17.23.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. The company had revenue of $21.55 million for the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. As a group, equities research analysts expect that Carlsmed will post -1.50 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Carlsmed

Hedge funds and other institutional investors have recently modified their holdings of the business. Jupiter Topco LLC acquired a new position in Carlsmed during the second quarter worth about $12,992,000. Janus Henderson Group PLC increased its stake in shares of Carlsmed by 7.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after acquiring an additional 86,834 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new stake in shares of Carlsmed in the 2nd quarter worth $6,200,000. BlackRock Inc. acquired a new stake in shares of Carlsmed in the 2nd quarter worth $5,528,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Carlsmed by 85.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 257,805 shares of the company’s stock worth $3,627,000 after acquiring an additional 118,663 shares during the period.

Carlsmed Company Profile

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients. Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.